Gastrodin, intranasal insulin, and cognitive training show greatest preventive effectiveness for postoperative cognitive dysfunction after cardiac surgery
Insulin, Gastrodin, and Training May Protect Brain After Heart Surgery
A systematic review and Bayesian network meta-analysis of 46 RCTs (9,928 patients) ranked 20 strategies for preventing postoperative cogniti…
A review of 46 trials suggests certain drugs and cognitive training may help prevent confusion and memory loss after cardiac surgery.
Esketamine reduces 3-month postpartum depression incidence from 20.89% to 11.59% in primiparae
Trial shows esketamine reduces postpartum depression risk in new mothers
This randomized controlled trial of 322 primiparae found that a single dose of esketamine significantly reduced the incidence of postpartum …
A clinical trial suggests that a single dose of esketamine during C-section surgery may lower the risk of developing postpartum depression.
Intranasal esketamine provides rapid acute improvement and reduced relapse risk in treatment-resistant depression
Esketamine shows rapid relief for treatment resistant depression
This meta-analysis of randomized controlled trials evaluated intranasal esketamine plus an oral antidepressant for treatment-resistant depre…
A new nasal spray combined with oral antidepressants can provide faster relief and lower relapse risks for people with treatment-resistant d…
Esketamine added to propofol maintains discharge readiness during outpatient flexible bronchoscopy
Trial shows esketamine addition helps patients recover from bronchoscopy
This randomized non-inferiority trial of 246 adults undergoing elective outpatient flexible bronchoscopy found that adding esketamine (0.1 m…
Adding a low dose of esketamine to propofol may help patients recover faster and cough less during outpatient bronchoscopy procedures.
Esketamine bolus reduces PPD incidence at 6 weeks to 9.15% compared to 19.33% in saline
Trial shows Esketamine bolus reduces postpartum depression risk
This randomized controlled trial of 503 subjects without prenatal depression undergoing caesarean delivery found that esketamine bolus signi…
A new trial suggests that an esketamine bolus can reduce the risk of postpartum depression following a cesarean delivery.
Esketamine significantly reduces postoperative anxiety (SMD -1.23) and depressive symptoms (SMD -0.92) in adult patients
Esketamine reduces anxiety and depression after surgery
This meta-analysis of 1,312 adults undergoing general anesthesia found that esketamine significantly reduced both anxiety and depression pos…
New data shows esketamine can significantly lower feelings of anxiety and depression in adults following surgery.
Meta-analysis finds esketamine improves response in treatment-resistant depression with dose-dependent adverse events
Esketamine for depression: higher dose, more side effects
This meta-analysis of 9 RCTs (1,449 patients) found that esketamine improved clinical response rates (RR=1.94) in treatment-resistant depres…
A new analysis finds esketamine helps treatment-resistant depression, but higher doses bring more nausea, dizziness, and dissociation.
Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression in real-world settings
Real-World Results Show Esketamine Cuts Depression Symptoms Fast
This systematic review and meta-analysis evaluates intranasal esketamine in adults with treatment-resistant depression across real-world set…
Depression symptoms dropped sharply and remission rates rose over three months in adults using esketamine nasal spray in routine clinics.
Esketamine vs fentanyl for pediatric tonsillectomy pain shows comparable FLACC scores
Esketamine and fentanyl ease kids' tonsil pain equally after surgery
This randomized controlled trial in 54 children scheduled for tonsillectomy compared esketamine 0.5 mg·kg to fentanyl 4 μg·kg at induction.
For kids getting tonsils out, esketamine and fentanyl control pain just as well, but esketamine keeps blood pressure steadier during surgery…
FDA Approves Spravato (esketamine) for Treatment-Resistant Depression and Depressive Symptoms with Acute Suicidal Ideation in Adults
The FDA approved a new nasal spray called Spravato for severe depression
The FDA approved Spravato (esketamine) for treatment-resistant depression in adults as monotherapy or with an oral antidepressant, and for d…
FDA approved a new nasal spray for severe depression when other treatments fail or when patients face acute suicidal thoughts.
Observational study links esketamine-induced mystical experiences to depression improvement in 45 patients
Mystical experiences during esketamine treatment linked to better depression outcomes in small study
In an observational study of 45 patients with treatment-resistant depression receiving esketamine at two centers, 58% experienced mystical e…
Patients with treatment-resistant depression who felt mystical effects from esketamine showed greater improvement, while other side effects …